Stoke Therapeutics, Inc. (STOK) is trading at $8.53, down 5.22 percent or $0.47 during Tuesday's trading, after reporting fourth-quarter results. Revenue for the quarter was $22.6 million, higher than the $2.8 million reported in the prior year.
The stock opened at $8.63 and has traded between $7.70 and $8.73 so far, compared to a previous close of $9.00 on the Nasdaq. Trading volume stands at 533,878 shares, below the average volume of 805,508. The stock's 52-week range is $5.60 to $17.58.
Moreover, the company posted a net loss of $10.5 million, or $0.18 per share, an improvement from a $27.0 million net loss, or $0.60 per share, in the same period of 2023.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.